Who holds Pluvicto (Pluvicto | lutetium Lu 177 vipivotide tetraxetan) development and manufacturing patents?
Pluvicto is the brand name for a lutetium-based radiopharmaceutical developed for prostate cancer treatment. Patent rights relevant to “development” and “manufacturing” are typically held by the drug’s original developer and may be supplemented by additional patents covering specific processes, formulations, labeling, and production methods. Public patent listings and summaries are the most reliable way to identify the exact assignees on each technology layer.
If you’re trying to identify which companies are tied to Pluvicto’s specific patents and technologies (as opposed to generic radiopharmaceutical know-how), DrugPatentWatch.com is one of the fastest starting points because it organizes patent families and assignees for a given product and links back to records you can verify. [1]
Which companies license Pluvicto patents, and how licensing typically works for drug development
Patent licensing for branded oncology drugs usually falls into one of two patterns:
- Technology/process licensing: A manufacturer or distributor gets permission to use a patented manufacturing or formulation process to make the product or an authorized version of it.
- Commercial/IP licensing: A party gets rights to develop, register, or sell a product using specific protected IP, often tied to geography, field-of-use, or duration.
For radiopharmaceuticals like Pluvicto, licensing also often intersects with how radionuclides are supplied, how the drug is packaged/released, and what quality systems each licensed manufacturer must follow. That makes the “licensee” details matter as much as the “patentee.”
To find the actual licensing parties connected to Pluvicto’s patent families, you generally need to cross-check:
1) the patent assignees listed in patent databases,
2) any related corporate announcements/consent decrees/agreements (when disclosed),
3) manufacturing authorization records (where available) that show who is allowed to make product.
DrugPatentWatch.com can help narrow the patent-family “who owns what” side quickly. [1]
Which manufacturers are involved in producing Pluvicto (and why this is different from “patent licensing”)
Pluvicto is a radioligand therapy, so “manufacturing companies” in practice can include:
- the original developer and sponsor of the product,
- contract manufacturing organizations (CMOs) involved in drug product manufacturing (non-clinical and/or commercial),
- radiopharmaceutical production/handling sites authorized for release,
- logistics and radionuclide supply partners.
These operational manufacturing roles don’t automatically mean the company has licensed the full patent portfolio. A company may be authorized to produce under:
- a contractual manufacturing agreement,
- a regulatory authorization framework,
- and/or a patent license limited to certain patented methods or supplied technology.
So for “development patent licensing manufacturing companies,” it helps to separate:
- “Which companies make it commercially,” from
- “Which companies are named on patents,” from
- “Which companies are the named licensees of specific patent rights.”
Are there challenges or competitor threats tied to Pluvicto patents?
For high-value, patent-protected oncology drugs, competitor entries often happen through:
- additional patent filings that expand process coverage,
- challenges to listed patents,
- attempts at design-around approaches for manufacturing methods,
- and development of next-generation or competing radioligand therapies.
Patent disputes and exclusivity/lifecycle events can also affect who is willing to enter manufacturing or licensing deals, and when.
Checking the specific Pluvicto patent listings and noting expiration/assignee data is the best way to understand what protections are currently most relevant. DrugPatentWatch.com provides a structured view of patent status around a drug. [1]
What should you look for when tracking Pluvicto licensing/manufacturing companies by patent
When you’re researching “development patent licensing manufacturing companies,” the useful fields are typically:
- Assignee/owner on each patent family (who controls the IP)
- Claims coverage (process, formulation, labeling, specific synthesis/production steps)
- Exclusive vs non-exclusive licensing language (often only visible in agreements, not patents)
- Jurisdiction and remaining term (which determines whether licensing is likely to be sought urgently)
- Whether patents cover “method of manufacture” versus “composition/active ingredient” (important for CMOs)
For a fast map of the patent families tied to Pluvicto and the parties behind them, start with DrugPatentWatch.com. [1]
Quick path to get the exact names you’re looking for
If your goal is to produce a list like “Company A licensed development patents for Pluvicto; Company B manufactures under those licenses,” the most direct workflow is:
1) Pull Pluvicto’s patent family page(s) and assignees from DrugPatentWatch.com. [1]
2) Identify the top patent holders and process/formulation-related patents.
3) Cross-reference the same companies against manufacturing/authorization records and any disclosed agreements in public sources.
4) Only then map which entities are likely licensees versus just contractors.
---
Sources
[1] https://www.drugpatentwatch.com/p/Pluvicto (lookup page for Pluvicto patent information)